Skip to main content
SpringerLink
Log in

Herausfordernde phasenadaptierte Behandlung

Moderne Therapie bipolarer Störungen

  • Zertifizierte Fortbildung Psychatrie
  • Published:
InFo Neurologie + Psychiatrie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

© A. Reif, Frankfurt am Main

2

© A. Reif, Frankfurt am Main

3

© C. Eckart, Frankfurt am Main

Literatur

  1. Merikangas KR et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011;68:241-51

  2. Rowland TA, Marwaha S. Epidemiology and risk factors for bipolar disorder. Ther Adv Psychopharmacol 2018;8:251-69

  3. Berk M et al. Staging in bipolar disorder: from theoretical framework to clinical utility. World Psychiatry Off J World Psychiatr Assoc WPA. 2017;16:236-44

  4. Pinto JV et al. What impact does bipolar disorder staging have on the use of pharmacotherapy? Expert Opin Pharmacother 2021;22:1513-6

  5. Gonda X et al. Suicidal behavior in bipolar disorder: epidemiology, characteristics and major risk factors. J Affect Disord 2012;143:16-26

  6. Crump C et al. Comorbidities and Mortality in Bipolar Disorder: A Swedish National Cohort Study. JAMA Psychiatry 2013;70:931-9

  7. Hayes JF et al. A systematic review and meta-analysis of premature mortality in bipolar affective disorder. Acta Psychiatr Scand 2015;131:417-25

  8. Grande I et al. Bipolar disorder. Lancet 2016;387:1561-72

  9. Vieta E et al. Bipolar disorders. Nat Rev Dis Primer 2018;4:18008

  10. Bauer M et al. S3-Leitlinie zur Diagnostik und Therapie Bipolarer Störungen. https://link.springer.com/10.1007/978-3-662-61153-1

  11. Pacchiarotti I et al. How to treat mania. Acta Psychiatr Scand 2020;142:173-92

  12. Kishi T et al. Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. Mol Psychiatry 2022;27:1136-44

  13. Cavazzoni PA et al. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J Clin Psychiatry 2006;67:107-13

  14. Li XB et al. Clozapine for treatment-resistant bipolar disorder: a systematic review. Bipolar Disord 2015;17:235-47

  15. Baldessarini RJ et al. Pharmacological treatment of adult bipolar disorder. Mol Psychiatry 2019;24:198-217

  16. Sachs GS et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007;356:1711-22

  17. McGirr A et al. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry 2016;3:1138-46

  18. Liu B et al. Efficacy and safety of long-term antidepressant treatment for bipolar disorders - A meta-analysis of randomized controlled trials. J Affect Disord 2017;223:41-8

  19. Young AH et al. Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. Int J Bipolar Disord 2013;1:10

  20. Li H et al. Efficacy and safety of quetiapine extended release monotherapy in bipolar depression: a multi-center, randomized, double-blind, placebo-controlled trial. Psychopharmacology 2016;233:1289-97

  21. Pinto JV et al. Cariprazine in the treatment of Bipolar Disorder: A systematic review and meta-analysis. Bipolar Disord 2020;22:360-71

  22. Bahji A et al. ECT beyond unipolar major depression: systematic review and meta-analysis of electroconvulsive therapy in bipolar depression. Acta Psychiatr Scand 2019;139:214-26

  23. Yee CS et al. Maintenance Pharmacological Treatment of Juvenile Bipolar Disorder: Review and Meta-Analyses. Int J Neuropsychopharmacol 2019;22:531-40

  24. Carvalho AF al. Treatment implications of predominant polarity and the polarity index: a comprehensive review. Int J Neuropsychopharmacol 2014;18:pyu079

  25. Kishi T et al. Effects of a conventional mood stabilizer alone or in combination with second-generation antipsychotics on recurrence rate and discontinuation rate in bipolar I disorder in the maintenance phase: A systematic review and meta-analysis of randomized, placebo-controlled trials. Bipolar Disord 2021;23:789-800

  26. Kessing LV et al. Effectiveness of maintenance therapy of lithium vs other mood stabilizers in monotherapy and in combinations: a systematic review of evidence from observational studies. Bipolar Disord 2018;

  27. Carvalho AF et al. Bipolar Disorder. N Engl J Med 2020;383:58-66

  28. Hayes JF et al. Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records. World Psychiatry Off J World Psychiatr Assoc WPA 2016;15:53-8

  29. Tondo L, Baldessarini RJ. Antisuicidal Effects in Mood Disorders: Are They Unique to Lithium? Pharmacopsychiatry 2018;51:177-88

  30. McKnight RF et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012;379:721-8

  31. Bauer M. [A new evidence and consensus-based German guidelines for diagnosis and treatment of bipolar disorders]. Nervenarzt 2012;83:564-7

  32. Tan MK et al. A Meta-Analysis of Group Cognitive Behavioral Therapy and Group Psychoeducation for Treating Symptoms and Preventing Relapse in People Living with Bipolar Disorder. Healthc Basel Switz 2022;10:2288

  33. Bond K, Anderson IM. Psychoeducation for relapse prevention in bipolar disorder: a systematic review of efficacy in randomized controlled trials. Bipolar Disord 2015;17:349-62

  34. Miklowitz DJ et al. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry 2021;78:141-50

  35. Miskowiak KW et al. Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force. Bipolar Disord 2022;24:354-74

  36. Veeh J et al. Cognitive remediation for bipolar patients with objective cognitive impairment: a naturalistic study. Int J Bipolar Disord 2017;5:8

  37. Vieta E et al. Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania. J Psychopharmacol 2021;35:971-82

  38. Sparacino G et al. Existing and emerging pharmacological approaches to the treatment of mania: A critical overview. Transl Psychiatry 2022;12:169

  39. Smith-Apeldoorn SY et al. The antidepressant effect and safety of non-intranasal esketamine: A systematic review. J Psychopharmacol 2022;36:531-44

  40. Joseph B et al. A Systematic Review on the Efficacy of Intravenous Racemic Ketamine for Bipolar Depression. J Clin Psychopharmacol 2021;41:71-5

  41. Diazgranados N et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010;67:793-802

  42. Zarate CA et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012;71:939-46

  43. Bahji A et al. Ketamine for Bipolar Depression: A Systematic Review. Int J Neuropsychopharmacol 2021;24:535-41

  44. Henriksen TE et al. Blue-blocking glasses as additive treatment for mania: a randomized placebo-controlled trial. Bipolar Disord 2016;18:221-32

Download references

Author information

Authors and Affiliations

  1. Klinik für Psychiatrie, Psychotherapie, Psychosomatik und Suchtmedizin, Evang. Kliniken Essen-Mitte, Henricistr. 92, 45136, Essen, Germany

    Martin Schäfer

  2. Klinikum der Johann Wolfgang Goethe-Universität, Klinik für Psychiatrie, Psychosomatik und Psychotherapie, Heinrich-Hoffmann-Str. 10, 60528, Frankfurt am Main, Germany

    Andreas Reif

Authors
  1. Martin Schäfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cindy Eckart
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Harald Scherk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christine Reif-Leonhard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sarah Kittel-Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andreas Reif
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Die Autorinnen und Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Sie legen folgende potenzielle Interessenkonflikte offen: A. Reif, C. Eckart, C. Reif-Leonhard, S. Kittel-Schneider: keine; M. Schäfer: Beratertätigkeit Janssen-Cilag, Vorstandsmitglied DGBS; H. Scherk: Honorare für Vorträge Medice und Janssen-Cilag.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags durch zwei unabhängige Gutachten bestätigt wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung.

Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schäfer, M., Eckart, C., Scherk, H. et al. Moderne Therapie bipolarer Störungen. InFo Neurologie 25, 40–49 (2023). https://doi.org/10.1007/s15005-023-3190-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-023-3190-2

Search

Navigation